Home » GLOBAL PHARMATECH RECEIVES SFDA CLINICAL APPROVAL
GLOBAL PHARMATECH RECEIVES SFDA CLINICAL APPROVAL
Global Pharmatech, a company which combines R&D of botanical drug products, manufacturing, and sales and marketing for the OTC and prescription drug markets, announced that Jilin BCT Pharmacy, a subsidiary of Global Pharmatech, has just received investigational new drug approval for its re-formulated herbal drug product, the YanLiXiao pill, from the State Food and Drug Administration of China. The company will soon commence clinical development of the YanLiXiao pill.
BioSpace (http://www.biospace.com/news_story.cfm?StoryID=20436020&full=1)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May